Enhertu for HER2-positive gastric cancer
Quick answer: Enhertu is used for HER2-positive gastric cancer as part of a her2-directed antibody-drug conjugate treatment regimen. Anti-HER2 monoclonal antibody conjugated to a topoisomerase I inhibitor (deruxtecan) that delivers cytotoxic payload to HER2-expressing tumor cells The specific dosing for HER2-positive gastric cancer is determined by your prescriber based on individual factors.
Why is Enhertu used for HER2-positive gastric cancer?
Enhertu belongs to the HER2-directed antibody-drug conjugate class. Anti-HER2 monoclonal antibody conjugated to a topoisomerase I inhibitor (deruxtecan) that delivers cytotoxic payload to HER2-expressing tumor cells This action makes it useful for treating or managing HER2-positive gastric cancer in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Enhertu is the right choice for a specific patient depends on the type and severity of HER2-positive gastric cancer, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for HER2-positive gastric cancer
Common adult dosing range: 5.4 mg/kg IV every 3 weeks. The actual dose for HER2-positive gastric cancer depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Enhertu medicine page.
What to expect
Enhertu treatment for HER2-positive gastric cancer typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on HER2-positive gastric cancer
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Enhertu is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all HER2-directed antibody-drug conjugate for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Enhertu
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Enhertu full prescribing information · All HER2-directed antibody-drug conjugate alternatives
Frequently asked questions
How effective is Enhertu for HER2-positive gastric cancer?
Effectiveness varies by individual response, dose, and severity. Enhertu is one of several treatment options for HER2-positive gastric cancer, supported by clinical evidence within the her2-directed antibody-drug conjugate class. Discuss expected response with your prescriber.
How long do I need to take Enhertu for HER2-positive gastric cancer?
Treatment duration depends on the nature of HER2-positive gastric cancer — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Enhertu when used for HER2-positive gastric cancer?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Enhertu for HER2-positive gastric cancer?
Yes. Multiple medicines and non-drug options exist for HER2-positive gastric cancer. Alternatives within the her2-directed antibody-drug conjugate class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.